Joseph Monahan - Mar 10, 2022 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: Chief Scientific Officer
Signature: /s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol: ACRS
Transactions as of: Mar 10, 2022
Transactions value $: -$426,803
Form type: 4
Date filed: 3/14/2022, 04:53 PM
Previous filing: Mar 3, 2022
Next filing: Apr 20, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRS	Common Stock	Sale	-$427K	-27.2K	-16.61%	$15.71	136K	Mar 10, 2022	Direct	F1, F2
holding	ACRS	Common Stock						193	Mar 10, 2022	By Spouse

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2022 and March 2, 2022 pursuant to preexisting sell-to-cover elections.
F2	The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.22 to $16.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2022 and March 2, 2022 pursuant to preexisting sell-to-cover elections.

The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.22 to $16.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.